MARIANI PETER J 4
4 · Cytosorbents Corp · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Cytosorbents (CTSO) CFO Peter Mariani Buys 100,000 Shares
What Happened
- Peter J. Mariani, Chief Financial Officer of Cytosorbents Corporation (CTSO), made open-market purchases totaling 100,000 shares on June 15, 2026. The reported weighted-average price was $0.44 per share, for an aggregate cost of approximately $44,000. This was a purchase (acquisition) transaction.
Key Details
- Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (timely filing).
- Transaction type/code: P = Purchase (open market).
- Price: weighted average $0.44; trades occurred at prices in the range $0.40–$0.45 (Reporting Person can provide per-trade breakdown on request).
- Shares acquired: 100,000; cash paid ≈ $44,000.
- Shares owned after transaction: 316,613 common shares (216,613 previously owned + 100,000 purchased), per the filing.
- Unvested/award holdings disclosed:
- 110,000 RSUs (settle on vesting upon a Change in Control or on Aug 14, 2028, subject to service).
- 65,000 RSUs (32,500 remain unvested; vest in two installments over two years).
- 175,000 RSUs (settle on a Change in Control).
- 71,500 RSUs (vest half on each of the first and second anniversaries of grant).
- No option exercises, gifts, or tax-withholding shares reported in this filing.
Context
- This was a straightforward open-market buy by the CFO. Purchases by executives are sometimes viewed by investors as a positive signal about their view of the company, but they do not prove future performance. The filing discloses both current owned shares and several unvested RSU awards that could convert to Common Stock under the conditions noted above.
Insider Transaction Report
Form 4
MARIANI PETER J
Chief Financial Officer
Transactions
- Purchase
Common Stock
[F1][F2][F3][F4][F5]2026-06-15$0.44/sh+100,000$44,000→ 638,113 total
Footnotes (5)
- [F1]The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;
- [F3](continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;
- [F4](continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and
- [F5](continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person.
Signature
/s/ Peter J. Mariani|2026-06-16